---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021864"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:19.545737+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Celcuity secures up to $180M debt financing, plans Phase 3 gedatolisib trial in HR+/HER2- breast cancer

## Summary
- New A&R Loan Agreement with Innovatus and Oxford provides up to $180M; $100M funded including $61.7M new borrowings.
- Loan matures May 2029; interest-only for 36 months (extendable to 48 months) at Prime + 2.85% (floor 7.75%).
- Phase 3 VIKTORIA-2 trial to enroll ~638 HR+/HER2- ABC patients; first patient expected Q2 2025.
- Trial design allows investigator choice of ribociclib or palbociclib; FDA concurred in Type C meeting.
- Warrants issued equal to 2.5% of each tranche; Innovatus can convert up to 20% of Term A at $10.00/share.

## SEC filing metadata
- accession: 0001493152-24-021864
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/0001493152-24-021864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021864
- JSON: https://secwatch.observer/filing/0001493152-24-021864.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.